Pelvic Floor Disorders Network 2015

骨盆底疾病网络第四周期更新- UT西南 项目总结/摘要 我们的主要目标是积极参与骨盆底疾病网络（PFDN），通过有效的 患者招募、参与和保留种族和人种多样化的患者人群 检查女性骨盆底疾病（PFDs）的研究。我们的第二个目标是将创新研究 向该网络提出建议，重点是探索病理生理学和预防的转化目标 明确定义的临床研究人群中的PFDs。为了实现这些目标，我们描述了资格 女性盆腔医学和重建外科（FPMRS）教师和研究的经验 德克萨斯大学西南医学中心和帕克兰医院的团队， 人口可用于执行临床协议，以及我们最先进的科学方法来研究 PFDs。本申请中描述的临床研究团队积极参与了PFDN的周期II， 为每项PFDN临床试验实现了稳健的招募和保留，包括主要研究中心招募， 随机分组用于抗胆碱能药与Botox®比较（“ABC”）。我们的临床和研究诊所既为 医疗贫困患者（帕克兰医院）和私人保险患者（大学实践）。这些诊所 提供多元化的患者群体，使我们成为西班牙裔女性的领先招募者 PFDN（周期II）。我们积极参与PFDN的各个方面，包括概念提案、委员会 参与和手稿准备。我们的研究团队的独特之处是泌尿妇科学基础， 翻译科学家，使我们的网站领导的努力，开发和实施ABC生物储存库的 PFDN在第三周期仍设在UT西南部，并已成为其他 翻译研究的努力。此外，我们妇产科的科学资源和基础设施 该部门集中关注基因组学，表观遗传学和基因调控在各个方面的作用 女性的健康。在整个第三周期，虽然不是一个完整的临床研究中心，但我们仍然致力于 我们的PFDN研究参与者的成功保留和长期随访; 80%的E-OPTIMAL患者（5- 术后1年研究）。此外，我们将继续为科学做出贡献， 出版物和持续的写作团队参与。2015年，新医院为UT和 西南部和帕克兰，FPMRS诊所的人口基数正在激增。UT的FPMRS医生 西南大学仍然致力于严格的对照试验，旨在客观地评估非 手术和手术护理与国防军的使命一致。随着越来越多的多样化的临床患者 人口，一个致力于和经验丰富的研究团队，具有成功的内部和外部的血统， 合作，以及支持其他转化PFD研究的资源和专业知识，UT 西南大学已经准备好并充满活力地返回PFDN作为一个完整的临床基地。

Pelvic Floor Disorders Network Cycle IV Renewal – UT Southwestern PROJECT SUMMARY / ABSTRACT Our primary goal is to actively engage in the Pelvic Floor Disorders Network (PFDN) through efficient patient recruitment, participation, and retention of a racially and ethnically diverse patient population in all studies examining pelvic floor disorders (PFDs) in women. Our second goal is to bring innovative research proposals to this Network with emphasis on translational aims that explore the pathophysiology and prevention of PFDs in well-defined clinical study populations. To accomplish these aims, we describe the qualifications and experience of the Female Pelvic Medicine and Reconstructive Surgery (FPMRS) faculty and research teams at the University of Texas Southwestern Medical Center and Parkland Hospital, the facilities and patient population available to carry out clinical protocols, and our state-of-the-art scientific approaches to the study of PFDs. The clinical research team described in this application actively participated in Cycle II of the PFDN and achieved robust recruitment and retention for every PFDN clinical trial, including leading site enrollment and randomization for anticholinergic vs Botox® comparison (“ABC”). Our clinical and research clinics serve both medically indigent patients (Parkland Hospital) and private, insured patients (university practice). These clinics provide a diverse patient population which allowed us to be the leading recruiter of Hispanic women in the PFDN (Cycle II). We were active in all aspects of the PFDN including concept proposal, committee participation, and manuscript preparation. Unique to our research team is a urogynecology basic and translational scientist whereby our site led the effort to develop and implement the ABC Biorepository for the PFDN, which has remained housed at UT Southwestern in Cycle III and has become integral to other translational research endeavors. Further, the scientific resources and infrastructure within our Ob/Gyn department are centrally focused on the role of genomics, epigenetics and gene regulation in various aspects of women's health. Throughout Cycle III, while not a full clinical site, we have remained committed to the successful retention and long-term follow-up of our PFDN study participants; 80% of E-OPTIMAL patients (5- year postoperative study) have been retained. Moreover, we continue to contribute scientifically with multiple publications and ongoing writing team participation. In 2015, new hospitals have opened for both UT Southwestern and Parkland, and the FPMRS clinic population base is surging. The FPMRS physicians at UT Southwestern remain dedicated to rigorous controlled trials intended to objectively evaluate principles of non- surgical and surgical care consistent with the mission of the PFDN. With a growing, diverse clinical patient population, a committed and seasoned research team with a pedigree of successful internal and external collaborations, and the resources and expertise to champion additional translational PFD research, UT Southwestern is ready and energized to return to the PFDN as a full clinical site.